Pharmaceutical - Asia-Pacific, Cardio-vascular

Filter

Popular Filters

1 to 25 of 39 results

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

13-02-2014

The Australian Competition and Consumer Commission revealed today that is has instituted proceedings…

Asia-PacificAustraliaCardio-vascularLegalLipitorMarkets & MarketingPfizerPharmaceutical

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

08-01-2014

Japanese drug major Daiichi Sankyo (TYO: 4568) has submitted a Marketing Authorization Application to…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulation

AstraZeneca and Shionogi settle Crestor arbitration

AstraZeneca and Shionogi settle Crestor arbitration

26-12-2013

Anglo-Swedish drug major AstraZeneca revealed yesterday (December 26) the full resolution of arbitration…

Asia-PacificAstraZenecaCardio-vascularCrestorGlobalLicensingPharmaceuticalShionogi

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Novartis under investigation for manipulating data in Japanese clinical trials

Novartis under investigation for manipulating data in Japanese clinical trials

27-09-2013

Swiss drug major Novartis has said it regrets the inconvenience caused by its investigator-initiated…

Asia-PacificCardio-vascularLegalNovartisPharmaceuticalRegulationvalsartan

Novartis' research study questioned in Japan

15-07-2013

Swiss drug major Novartis (NOVN: VX) has admitted that there was an undisclosed conflict of interest…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalResearch

Pharming and SIPI collaboration includes Ruconest marketing in China

02-07-2013

Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

SciClone and Taiwan Liposome link up on ProFlow for China

26-06-2013

USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) yesterday (June 25) has announced an agreement with…

Asia-PacificCardio-vascularLicensingPharmaceuticalProFlowSciClone PharmaTaiwan Liposome

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

India's NPPA to slash prices of key drugs by up to half

17-06-2013

In India, some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis…

Asia-PacificCardio-vascularOncologyPharmaceuticalPricing

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

SciClone gains China rights to Zensun's Neucardin

20-05-2013

USA-based SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the Company has entered into an…

Asia-PacificCardio-vascularLicensingNeucardinPharmaceuticalSciClone PharmaZensun

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Kowa and Daiichi Sankyo to end joint marketing partnership in Japan

07-04-2013

Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending…

Asia-PacificCardio-vascularDaiichi SankyoKowa PharmaceuticalsLicensingLivaloMarkets & MarketingOlmetecPharmaceutical

Proposal to list AstraZeneca's Brilinta in New Zealand

26-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…

Asia-PacificAstraZenecaBrilintaCardio-vascularFinancialHealthcarePharmaceuticalPricingticagrelor

Daiichi Sankyo updates on PRASFIT-Elective study, NDA filing

14-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that the follow-up period for the Phase III PRASFIT-Elective…

Asia-PacificAspirinCardio-vascularDaiichi SankyoEffientPharmaceuticalprasugrelRegulationResearch

Further savings expected following Australian Crestor patent decision, says GMiA

07-03-2013

In a decision brought down by the Australian Federal Court earlier this week, suppliers of generic medicines…

Asia-PacificAstraZenecaCardio-vascularCrestorGenericsPatentsPharmaceuticalPricing

AstraZeneca's Crestor patent rule invalid in Australia

05-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that the Federal Court of Australia…

Asia-PacificAstraZenecaCardio-vascularCrestorPatentsPharmaceutical

1 to 25 of 39 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top